{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:12:40Z","timestamp":1789560760391,"version":"build-2803163510"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives.<\/jats:title>\n                    <jats:p>During the 2024-2025 respiratory syncytial virus (RSV) season, a universal nirsevimab infant immunization program was implemented in the province of Qu\u00e9bec. We evaluated its population-level impact on RSV-related emergency department (ED) visits and hospitalizations in 0-5-month-old infants, using both active surveillance and administrative health data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Study population included all Qu\u00e9bec children &lt;18 years old. We calculated incidence rates of RSV-confirmed hospitalizations, RSV-associated hospitalizations and ED visits linked to a positive RSV test, and acute bronchiolitis ED visits for nirsevimab-eligible (0-5 months old) and non-eligible (6-11 months and 1-17 years old) age groups during the 2024-2025 season. We also compared these 2024-2025 figures to previous seasons using varying lookback periods. Using difference-in-differences and constant proportion of admissions counterfactual approaches, pre-\/post-intervention variations in 0-5-month-olds were adjusted for any time trends occurring in non-targeted age groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Decreases of 59% (95% CI: 49\u201370) and 66% (95% CI: 58\u201371) were observed in RSV-confirmed and RSV-associated hospitalizations, respectively. Acute bronchiolitis ED visits decreased by 35% (95% CI: 28\u201341), and RSV-associated ED visits by 60% (95% CI: 56\u201365). In the 2024-25 season, ED visits and hospitalizations were less frequent than expected (i.e. without nirsevimab) in 0-5-month-old infants, suggesting that between 323 and 746 hospitalizations may have been prevented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>The 2024-2025 nirsevimab campaign was associated with a two-thirds reduction in RSV-related hospitalizations and RSV-associated ED visits in Qu\u00e9bec among 0-5-month-old infants. ED visits for acute bronchiolitis were also reduced by a third.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ede.0000000000002050","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:00:13Z","timestamp":1789560013000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of the first nirsevimab immunization campaign on infant RSV-related emergency department visits and hospitalizations in Qu\u00e9bec, Canada"],"prefix":"10.1097","author":[{"given":"Amandine","family":"Bemmo","sequence":"first","affiliation":[{"name":"Axe Maladies infectieuses et immunitaires, Centre de recherche du Centre hospitalier universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lise","family":"Fortin","sequence":"additional","affiliation":[{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."},{"name":"D\u00e9partement de microbiologie, infectiologie et immunologie, Facult\u00e9 de m\u00e9decine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Fortin","sequence":"additional","affiliation":[{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhouene","family":"Doggui","sequence":"additional","affiliation":[{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles-Antoine","family":"Guay","sequence":"additional","affiliation":[{"name":"Axe Maladies infectieuses et immunitaires, Centre de recherche du Centre hospitalier universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."},{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."},{"name":"Centre de Recherche de l\u2019Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec, Qu\u00e9bec, QC, Canada."},{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Amini","sequence":"additional","affiliation":[{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Carazo","sequence":"additional","affiliation":[{"name":"Axe Maladies infectieuses et immunitaires, Centre de recherche du Centre hospitalier universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."},{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."},{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Papenburg","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children\u2019s Hospital, McGill University Health Centre, Montreal, QC, Canada"},{"name":"Division of Microbiology, Department of Clinical Laboratory Medicine, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodica","family":"Gilca","sequence":"additional","affiliation":[{"name":"Axe Maladies infectieuses et immunitaires, Centre de recherche du Centre hospitalier universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."},{"name":"Direction des risques biologiques. Institut national de sant\u00e9 publique du Qu\u00e9bec, Qu\u00e9bec, QC, Canada."},{"name":"D\u00e9partement de m\u00e9decine sociale et pr\u00e9ventive, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,15]]},"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000002050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:00:14Z","timestamp":1789560014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/EDE.0000000000002050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000002050","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"value":"1044-3983","type":"print"},{"value":"1531-5487","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}